Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

Christian Glennie

Edison Investment Research

Image: Christian Glennie

Christian Glennie joined the healthcare team at Edison Investment Research in January 2012 and has 11 years' experience covering the global biotech/pharmaceutical sector as an analyst and a journalist. He came to Edison having held senior analyst and editorial roles at EvaluatePharma and EP Vantage. Christian Glennie also has prior experience as a marketing analyst at Zeneca Agrochemicals.




Recent Interviews

Seven Biotech Options that Buck Tradition: Christian Glennie (6/6/13) Edison Investment Research assesses the value of emerging companies with a model that assumes revenues and earnings are years away. Then again, every investor does that. What's unusual is that Edison looks for tomorrow's upside in companies still small enough to double, triple and quadruple in value down the line. In this interview with The Life Sciences Report, Edison Biotechnology Analyst Christian Glennie applies his valuation skills to seven innovative biotech and specialty pharma companies and discusses the share-moving catalysts that investors need to know about now.

Recent Quotes

"Positive Phase 2 data in ischemic stroke could rerate ATHX's stock." (9/24/14) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"ATHX's Phase 2, ischemic stroke study results are expected in Q4/14." (6/30/14) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"Potential FDA clearance for VRS' Aura is a key near-term catalyst." (6/30/14) Verisante Technology Inc. - Christian Glennie, Edison Investment Research More >

"A key, near-term catalyst for VRS is 501(k) FDA clearance for Aura." (6/2/14) Verisante Technology Inc. - Christian Glennie, Edison Investment Research More >

"ATHX is well capitalized with $45M in cash at Q1/14E." (5/6/14) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"ATHX's big cash balance will allow it to fully exploit MultiStem's undeniable potential." (1/21/14) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"Results in 2014 from ATHX's phase 2 studies could rerate the stock." (12/2/13) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"ATHX's encouraging phase 1 trials have demonstrated MultiStem's safety and efficacy." (10/25/13) Athersys Inc. - Christian Glennie, Edison Investment Research More >

more comments

"A $2.8M research grant enables ATHX's MultiStem to enter a third phase 2 trial to evaluate the safety and therapeutic impact of its allogeneic adult stem cells." (8/9/13) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"ATHX showed MultiStem increases long term survival of organ transplants." (7/16/13) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"Positive results from ATHX's phase 2 MultiStem trial could catalyze the stock and lead to a lucrative licensing deal." (6/26/13) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"ATHX is an exciting story and definitely a company to watch." (6/6/13) Athersys Inc. - The Life Sciences Report Interview with Christian Glennie More >

"ATHX has gained 25% in the last month; we see its enterprise value rising further." (5/7/13) Athersys Inc. - Christian Glennie, Edison Investment Research More >

fewer comments


Due to permission requirements, not all quotes are shown.